Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
LEXINGTON, Mass. and LONDON, April 30, 2018 -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8 at 4:10 p.m. ET in Boston, MA.
To access the live webcast, please visit ir.nightstartx.com. A replay of the webcast will be available on the Nightstar website for two weeks following the conference.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar’s lead product candidate, NSR-REP1, is currently in Phase 3 development for the treatment of patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments. Results from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in 2014 and in The New England Journal of Medicine in 2016. Nightstar’s second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease.
For more information about Nightstar or its clinical trials, please visit www.nightstartx.com.
Contacts:
Senthil Sundaram, Chief Financial Officer
Brian Luque, Sr. Manager, Investor Relations
[email protected]
